William Fattig, MD
Internal Medicine · Alliance, NENPI 1811071442
Payments from drug & device makers
Across 145 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$703
- Otsuka America Pharmaceutical, Inc.$373
- AbbVie$192
- Collegium Pharmaceutical, Inc.$151
- AstraZeneca$92
- Novartis$67
- plus $664 from 21 others
What the payments were for
- Food & beverage$2,243100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 51 | $703 |
| Otsuka America Pharmaceutical, Inc. | 17 | $373 |
| AbbVie(2 entities) | 10 | $192 |
| Collegium Pharmaceutical, Inc. | 12 | $151 |
| AstraZeneca | 7 | $92 |
| Novartis | 4 | $67 |
| Sanofi-aventis U.S. LLC | 5 | $63 |
| Lilly USA, LLC | 4 | $58 |
| Sanofi | 3 | $58 |
| Pfizer | 4 | $57 |
| Merck | 4 | $48 |
| Pharming Healthcare, Inc. | 3 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Viatris Specialty LLC | 2 | $31 |
| Johnson & Johnson | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Eisai Inc. | 2 | $25 |
| Vertex | 1 | $20 |
| Shield Therapeutics Inc | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Metacel Pharmaceuticals LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Athena Bioscience, LLC | 1 | $13 |
How this compares
$2,243 in reported general payments places this provider in the 85th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 49 | $227,593 |
| EliquisApixaban | 161 | $95,451 |
| ErtapenemErtapenem Sodium | 89 | $42,427 |
| XareltoRivaroxaban | 63 | $40,727 |
| JardianceEmpagliflozin | 34 | $35,398 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 57 | $35,059 |
| OzempicSemaglutide | 19 | $26,479 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $24,124 |
| FarxigaDapagliflozin Propanediol | 31 | $17,498 |
| JanuviaSitagliptin Phosphate | 28 | $17,489 |
| Spiriva HandihalerTiotropium Bromide | 32 | $17,239 |
| RexultiBrexpiprazole | 14 | $16,494 |
| TrintellixVortioxetine Hydrobromide | 44 | $15,854 |
| VraylarCariprazine Hcl | 11 | $15,654 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $14,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $57 | $95,451161 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $92 | $63,828137 claims |
| Johnson & JohnsonXarelto | $29 | $40,72763 claims |
| MerckJanuvia | $48 | $17,48928 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $373 | $16,49414 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $16 | $15,85444 claims |
| AbbVieVraylar | $192 | $15,65411 claims |
| Lilly USA, LLCTrulicity | $58 | $12,53314 claims |
| NovartisEntresto | $67 | $7,08511 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $151 | $3,22318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Alliance
- Scott RasmussenLincoln$38.1M
- Charles HarperNorfolk$31.1M
- Robert SchwabBoys Town$9.2M
- Michael DunnOmaha$7.9M
- Alexander RyanLincoln$2.2M
- Joel MichalskiOmaha$1.6M
- Ariana BauerOmaha$1.5M
- David CrockettOmaha$821K
- Timothy HuyckPapillion$702K
- Jason PottsLincoln$686K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.